Evaluación de la eficacia de la atención farmacéutica en pacientes con dermatitis atópica

  1. RAFAEL LOZANO FERNANDEZ
  2. PILAR GÓMEZ-SERRANILLOS CUADRADO
  3. MARTA SÁNCHEZ GÓMEZ-SERRANILLOS
  4. IRENE IGLESIAS PEINADO
  5. ROCIO SÁNCHEZ LANDETE
Revue:
Pharmaceutical care España

ISSN: 1139-6202

Année de publication: 2019

Volumen: 21

Número: 3

Pages: 159-178

Type: Article

D'autres publications dans: Pharmaceutical care España

Résumé

Introduction: Atopic dermatitis is an inflammatory and chronic skin disease that greatly affects the quality of life of patients suffering from it. Objective: To evaluate the efficacy of pharmaceutical care in patients with diagnosed atopic dermatitis, assessing its impact on symptomatology and adherence to treatment. Methods: A prospective longitudinal experimental study was conducted in 50 patients with uncontrolled atopic dermatitis, and an individualized pharmaceutical action was carried out based on three strategies: health education, pharmacotherapeutic follow-up, and intervention on the dermocosmetic routine. The symptomatology and adherence to the pharmacological treatment of each patient, and their evolution after the intervention were evaluated. Results: The data obtained were analyzed by means of the McNemar statistical test, confirming that 79.17% of the serious patients and 92.30% of the moderate cases improved significantly after the intervention. The value obtained from the statistic (Z = 3.49) indicated that the variables pharmaceutical intervention and patient improvement were not independent, the former being the cause of the latter. At the beginning of the study, 42% of the patients were noncompliant, while at the end of the study only 23.81% were noncompliant. Conclusion: This study demonstrates that pharmaceutical care, and more specifically pharmacotherapy follow-up, are useful and necessary tools to reduce symptomatology and improve the quality of life of patients with atopic dermatitis.